| New Agent/Combo | Desired Effect |
|---|---|
| Pazopanib and Tivantinib | Disrupts blood vessel formation and the MET pathway |
| MK-2206 and AZD6244 | Disrupts both AKT and MEK pathways (Merck and AstraZeneca drugs) |
| Cyclophosphamide and Veliparib | Damages tumor DNA and PARP inhibitor prevents its repair |
| EZN-2208 and Bevacizumab | Disrupts cancer’s DNA replication with longer acting version of the active form of camptothecin 11 that inhibits topoisomerase 1 and blocks new blood vessel formation (Enzon drug) |
| Belinostat | Turns silenced genes back on to limit cancer’s growth. Being evaluated in patients with liver abnormalities |
| Z-Endoxifen | Disrupts estrogen-receptor-driven growth in patients with hormone positive cancers |
| Vorinostat | Turns silenced genes back on to limit cancer’s growth; being tested as a treatment for adenoid cystic cancer, a rare disease |
| Phase 0 trial of IPdR Absorption, Metabolism, and Safety | Tests whether IPdR is absorbed in humans to eventually develop it as an oral radiosensitizer |
| EZN-2968 | Blocks the hypoxia inducible factor 1 alpha (HIF) production (Enzon drug) |
| Indenoisoquinolines LMP400 and LMP776 | Blocks topoisomerase 1 needed to cut DNA during cancer cell’s replication (non-camptothecin inhibitors) |